

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/758,683	01/14/2004	Jeannette Whitcomb	11068-078-999	4994
JONES DAY	7590 07/25/200	8	EXAM	IINER
222 East 41st Street			PARKIN, JEFFREY S	
New York, NY	7 10017		ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			07/25/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# 

The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 23 MONTH(S) OR THIRTY (30) DAYS WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  Extensions of time may be a valiable under the provisions of 37 CPT s1 136(a). In no event, may a reply be timely filed after SIX (6) MONTHS from the maining date of this communication. The state of th			
Status			
1) Responsive to communication(s) filed on 28 April 2008.			
2a) ☐ This action is FINAL. 2b) ☐ This action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is			
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4)⊠ Claim(s) <u>83-86</u> is/are pending in the application.			
4a) Of the above claim(s) is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.			
☑ Claim(s) <u>83-86</u> is/are rejected.			
7)⊠ Claim(s) <u>86</u> is/are objected to.			
8) Claim(s) are subject to restriction and/or election requirement.			
Application Papers			
9)☐ The specification is objected to by the Examiner.			
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:			
<ol> <li>Certified copies of the priority documents have been received.</li> </ol>			
<ol><li>Certified copies of the priority documents have been received in Application No</li></ol>			
3. Copies of the certified copies of the priority documents have been received in this National Stage			
application from the International Bureau (PCT Rule 17.2(a)).			
* See the attached detailed Office action for a list of the certified copies not received.			

Attachment(s)	
Automient(s)	
Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date
3) Information Displosure Statement(s) (PTO/SE/08)	5) Notice of Informal Patent Application
Paper No(s)/Mail Date	6) Other:
S. Patent and Trademark Office	-,

#### Detailed Office Action

#### Status of the Claims

Acknowledgement is hereby made of receipt and entry of the communication filed 28 April, 2008. Claims 83-86 are pending in the instant application.

## 35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C.  $\S$  112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

#### Scope of Enablement

The previous rejection of claims 83-89 under 35 U.S.C. § 112, first paragraph, because the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims, is hereby withdrawn in response to applicant's amendment.

#### 35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35  $\text{U.s.C.} \ \$ \ 112:$ 

The specification shall conclude with one or more claims particularly pointing out and distinctly

claiming the subject matter which the applicant regards as his invention.

Claims 83-86 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Two separate requirements are set forth under this statute: (1) the claims must set forth the subject matter that applicants regard as their invention; and (2) the claims must particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant. The claims are vague and indefinite because they fail to set forth the salient characteristics of the claimed methodology. See M.P.E.P. § 2172.01. Applicant is reminded that attempts to claim a process without setting forth any steps involved in the process generally raises an issue of indefiniteness under 35 U.S.C. § 112, second paragraph. For example, a claim which read: "A process for using monoclonal antibodies of claim 4 to isolate and purify human fibroblast interferon." was held to be indefinite because it merely recites a use without any active, positive steps delimiting how this use is actually practiced. Ex parte Erlich, 3 U.S.P.Q.2d 1011 (Bd. Pat. App. & Inter. 1986). The claimed methodology references an evaluating step but fails to set forth any active method steps (i.e., is the mutation being detected at the genotypic or phenotypic level?). Appropriate correction is required. The following suggested claim language would obviate the rejection: A method of assessing the effectiveness of a non-nucleoside transcriptase inhibitor (NNRTI) on a human immunodeficiency virus type 1 (HIV-1)-infected patient comprising detecting in a

plasma sample collected from said patient, the presence of an HIV-1 reverse transcriptase (RT) nucleic acid that encodes one of the following mutations: G190A/S and K101E, or G190A/S and A98G, wherein said mutation is associated with increased susceptibility to delavirdine (DLV) and decreased susceptibility to nevirapine (NVP) and efavirenz (EFV).

### Claim Objections

Claim 86 is objected to because it contains a typographical error. The claim should read "The method of claim 85 wherein ...". Appropriate correction is required.

#### Action Is Final, Necessitated by Amendment

Applicant's amendment necessitated any and all new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See M.P.E.P. § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 C.F.R. § 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. An attempt was made to contact applicant's representative on 18 July, 2008, to resolve any remaining issues. Applicant's

representative is invited to contact the examiner if they have any additional questions/concerns pertaining to the proposed claim language.

#### Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

/Jeffrey S. Parkin, Ph.D./ Primary Examiner, Art Unit 1648

20 July, 2008